Use of colistin-containing products within the European Union and European Economic Area (EU/EEA): development of resistance in animals and possible impact on human and animal health

International Journal of Antimicrobial Agents

Volumn 46, Issue 3, 2015, Pages 297-306

  Catry, Boudewijn ^a   Cavaleri, Marco ^b   Baptiste, Keith ^c   Grave, Kari ^b   Grein, Kornelia ^b   Holm, Anja ^c   Jukes, Helen ^d   Liebana, Ernesto ^e   Navas, Antonio Lopez ^f   Mackay, David ^b   Magiorakos, Anna Pelagia ^g   Romo, Miguel Angel Moreno ^h   Moulin, Gérard ⁱ   Madero, Cristina Muñoz ^f   Pomba, Maria Constança Matias Ferreira ^j   Powell, Mair ^k   Pyörälä, Satu ^l   Rantala, Merja ^l   Ružauskas, Modestas ^m   Sanders, Pascal ⁱ   Teale, Christopher ⁿ   Threlfall, Eric John ^o   Törneke, Karolina ^p   Van Duijkeren, Engeline ^q   Edo, Jordi Torren ^b,r   more..

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b EUROPEAN MEDICINES AGENCY   (United Kingdom)

^c Danish Health and Medicines Agency   (Denmark)

^d Veterinary Medicines Directorate   (United Kingdom)

^e EUROPEAN FOOD SAFETY AUTHORITY   (Italy)

^f Veterinary Medicines Department   (Spain)

^g EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^h UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

ⁱ Laboratoire de Fougères   (France)

^j UNIVERSITY OF LISBON   (Portugal)

^k MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^l UNIVERSITY OF HELSINKI   (Finland)

^m LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

ⁿ VETERINARY LABORATORIES AGENCY   (United Kingdom)

^o Consultant Clinical Scientist ^*  (United Kingdom)

^p MEDICAL PRODUCTS AGENCY   (Sweden)

^q NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^r UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

more..

Author keywords

Colistin; Healthcare associated infections; Livestock; Resistance

Indexed keywords

CARBAPENEM DERIVATIVE; COLISTIMETHATE; COLISTIN; POLYMYXIN B; RIFAMPICIN; TIGECYCLINE; ANTIINFECTIVE AGENT;

ACINETOBACTER INFECTION; ACUTE KIDNEY TUBULE NECROSIS; ADJUVANT THERAPY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; APNEA; ARTICLE; ATAXIA; BACTEREMIA; BACTERIAL TRANSMISSION; BACTERICIDAL ACTIVITY; BIOFILM; CONFUSION; DIARRHEA; DIZZINESS; DRUG POTENTIATION; DRUG UNDERDOSE; ENDOTOXEMIA; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI INFECTION; GASTROINTESTINAL INFECTION; GENE MUTATION; GRAM NEGATIVE INFECTION; HEALTHCARE ASSOCIATED INFECTION; HORIZONTAL GENE TRANSFER; HUMAN; INFECTION PREVENTION; INTRAMAMMARY DRUG ADMINISTRATION; KLEBSIELLA PNEUMONIAE INFECTION; LOADING DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OFF LABEL DRUG USE; PARESTHESIA; PERITONITIS; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RESPIRATORY FAILURE; SKIN INFECTION; STREPTOCOCCUS INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; VERTIGO; VETERINARY MEDICINE; VISUAL DISORDER; WEAKNESS; ZOONOSIS; ACINETOBACTER BAUMANNII; ANIMAL; BACTERIAL INFECTIONS; CHEMOPROPHYLAXIS; DRUG EFFECTS; ENTEROBACTERIACEAE; EUROPEAN UNION; MICROBIOLOGY; PROCEDURES; PSEUDOMONAS AERUGINOSA; VETERINARY;

ACINETOBACTER BAUMANNII; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHEMOPREVENTION; COLISTIN; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; EUROPEAN UNION; HUMANS; PSEUDOMONAS AERUGINOSA;

EID: 84940461663     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.06.005     Document Type: Review

References (112)

1. Y. Koyama, A. Kurosasa, A. Tsuchiya, and K. Takakuta A new antibiotic 'colistin' produced by spore-forming soil bacteria J Antibiot (Tokyo) 3 1950 457 458
2. J. Koch-Weser, V.W. Sidel, E.B. Federman, P. Kanarek, D.C. Finer, and A.E. Eaton Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy Ann Intern Med 72 1970 857 868
3. M.E. Falagas, and S.K. Kasiakou Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections Clin Infect Dis 40 2005 1333 1341
4. N.M. Nord, and P.D. Hoeprich Polymyxin B and colistin. A critical comparison N Engl J Med 270 1964 1030 1035
5. K.J. Ryan, L.I. Schainuck, R.O. Hickman, and G.E. Striker Colistimethate toxicity. Report of a fatal case in a previously healthy child J Am Med Assoc 207 1969 2099 2101
6. A.P. Magiorakos, A. Srinivasan, R.B. Carey, Y. Carmeli, M.E. Falagas, C.G. Giske, and et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance Clin Microbiol Infect 18 2012 268 281
7. R.L. Nation, and J. Li Colistin in the 21st century Curr Opin Infect Dis 22 2009 535 543
8. S.E. Cosgrove The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs Clin Infect Dis 42 2006 S82 S89
9. C. Schorr Performance improvement in the management of sepsis Crit Care Clin 25 2009 857 867
10. P.J. Bergen, J. Li, C.R. Rayner, and R.L. Nation Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa Antimicrob Agents Chemother 50 2006 1953 1958
11. J. Li, R.L. Nation, J.D. Turnidge, R.W. Milne, K. Coulthard, C.R. Rayner, and et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections Lancet Infect Dis 6 2006 589 601
12. L.M. Lim, N. Ly, D. Anderson, J.C. Yang, L. Macander, A. Jarkowski, 3rd, and et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing Pharmacotherapy 30 2010 1279 1291
13. M.J. Ledson, M.J. Gallagher, C. Cowperthwaite, R.P. Convery, and M.J. Walshaw Four years' experience of intravenous colomycin in an adult cystic fibrosis unit Eur Respir J 12 1998 592 594
14. J.M. Pogue, D. Marchaim, D. Kaye, and K.S. Kaye Revisiting 'older' antimicrobials in the era of multidrug resistance Pharmacotherapy 31 2011 912 921
15. J.A. Bosso, C.A. Liptak, D.K. Seilheimer, and G.M. Harrison Toxicity of colistin in cystic fibrosis patients DICP 25 1991 1168 1170
16. M.D. Reed, R.C. Stern, M.A. O'Riordan, and J.L. Blumer The pharmacokinetics of colistin in patients with cystic fibrosis J Clin Pharmacol 41 2001 645 654
17. P. Beringer The clinical use of colistin in patients with cystic fibrosis Curr Opin Pulm Med 7 2001 434 440
18. M.E. Falagas, E.K. Vouloumanou, and P.I. Rafailidis Systemic colistin use in children without cystic fibrosis: a systematic review of the literature Int J Antimicrob Agents 33 503 2009 e1 e13
19. A.F. Mohamed, I. Karaiskos, D. Plachouras, M. Karvanen, K. Pontikis, B. Jansson, and et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill Antimicrob Agents Chemother 56 2012 4241 4249
20. S.M. Garonzik, J. Li, V. Thamlikitkul, D.L. Paterson, S. Shoham, J. Jacob, and et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients Antimicrob Agents Chemother 55 2011 3284 3294
21. G. Vicari, S.R. Bauer, E.A. Neuner, and S.W. Lam Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant Gram-negative bacteremia Clin Infect Dis 56 2013 398 404
22. H. He, J.C. Li, R.L. Nation, J. Jacob, G. Chen, H.J. Lee, and et al. Pharmacokinetics of four different brands of colistimethate and formed colistin in rats J Antimicrob Chemother 68 2013 2311 2317
23. European Pharmacopoeia Council of Europe, European Public Health Committee, Maisonneuve; 2013.
24. M. Vaara, and T. Vaara The novel polymyxin derivative NAB739 is remarkably less cytotoxic than polymyxin B and colistin to human kidney proximal tubular cells Int J Antimicrob Agents 41 2013 292 293
25. P. Zarb, B. Coignard, J. Griskeviciene, A. Muller, V. Vankerckhoven, K. Weist, and et al. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use Eurosurveillance 17 2012 pii: 20316
26. G.L. Daikos, A. Markogiannakis, M. Souli, and L.S. Tzouvelekis Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective Exp Rev Anti Infect Ther 10 2012 1393 1404
27. N. Petrosillo, M. Giannella, R. Lewis, and P. Viale Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art Expert Rev Anti Infect Ther 11 2013 159 177
28. R. Cantón, M. Akóva, Y. Carmeli, C.G. Giske, Y. Glupczynski, M. Gniadkowski, and et al. European network on carbapenemases. Rapid evolution and spread of carbapenemases among enterobacteriaceae in Europe Clin Microbiol Infect 18 2012 413 431
29. K.K. Kumarasamy, M.A. Toleman, T.R. Walsh, J. Bagaria, F. Butt, R. Balakrishnan, and et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study Lancet Infect Dis 10 2010 597 602
30. G. Cornaglia, H. Giamarellou, and G.M. Rossolini Metallo-β-lactamases: a last frontier for β-lactams? Lancet Infect Dis 11 2011 381 393
31. P. Bogaerts, A. Verroken, B. Jans, O. Denis, and Y. Glupczynski Global spread of New Delhi metallo-β-lactamase 1 Lancet Infect Dis 10 2010 831 832
32. T.D. Huang, P. Bogaerts, C. Berhin, B. Jans, A. Deplano, O. Denis, and et al. Rapid emergence of carbapenemase-producing enterobacteriaceae isolates in Belgium Euro Surveill 16 2011 pii:19900
33. C. Glasner, B. Albiger, G. Buist, A. Tambić Andrasević, R. Canton, Y. Carmeli, and et al. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries February 2013 Eurosurveillance 18 2013 pii:20525
34. M. Tumbarello, P. Viale, C. Viscoli, E.M. Trecarichi, F. Tumietto, A. Marchese, and et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy Clin Infect Dis 55 2012 943 950
35. Z.A. Qureshi, D.L. Paterson, B.A. Potoski, M.C. Kilayko, G. Sandovsky, E. Sordillo, and et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens Antimicrob Agents Chemother 56 2012 2108 2113
36. E. Durante-Mangoni, G. Signoriello, R. Andini, A. Mattei, M. De Cristoforo, P. Murino, and et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial Clin Infect Dis 57 2013 349 358
37. A. Michalopoulos, and M.E. Falagas Colistin and polymyxin B in critical care Crit Care Clin 24 2008 377 391
38. P. Rattanaumpawan, J. Lorsutthitham, P. Ungprasert, N. Angkasekwinai, and V. Thamlikitkul Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria J Antimicrob Chemother 65 2010 2645 2649
39. Q. Lu, R. Luo, L. Bodin, J. Yang, N. Zahr, A. Aubry, and et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii Anesthesiology 117 2012 1335 1347
40. A. Capone, M. Giannella, D. Fortini, A. Giordano, M. Meledandri, M. Ballardini, and et al. SEERBIO-GRAB network. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality Clin Microbiol Infect 19 2013 E23 E30
41. K. Kontopoulou, E. Protonotariou, K. Vasilakos, M. Kriti, A. Koteli, E. Antoniadou, and et al. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 β-lactamase resistant to colistin J Hosp Infect 76 2010 70 73
42. O. Zarkotou, S. Pournaras, E. Voulgari, G. Chrysos, A. Prekates, D. Voutsinas, and et al. Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study J Clin Microbiol 48 2010 2271 2274
43. G. Meletis, E. Tzampaz, E. Sianou, I. Tzavaras, and D. Sofianou Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae J Antimicrob Chemother 66 2011 946 947
44. E.A. Oostdijk, L. Smits, A.M. de Smet, M.A. Leverstein-van Hall, J. Kesecioglu, and M.J. Bonten Colistin resistance in Gram-negative bacteria during prophylactic topical colistin use in intensive care units Intensiv Care Med 39 2013 653 660
45. T. Halaby, N. Al Naiemi, J. Kluytmans, J. van der Palen, and C.M. Vandenbroucke-Grauls Emergence of colistin resistance in enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit Antimicrob Agents Chemother 57 2013 3224 3229
46. European Medicines Agency, European Surveillance of Veterinary Antimicrobial Consumption (EMA/ESVAC). Sales of veterinary antimicrobial agents in 26 EU/EEA countries in 2012. Fourth ESVAC report. European Medicines Agency. p. 1-115. 2014 [accessed 09.06.15].
47. L. Renard, P. Sanders, and M. Laurentie Pharmacokinetics of colistin sulfate administered by intravenous and intramuscular routes in the calf [in French] Ann Rech Vet 22 1991 387 394
48. M.H. Barton, A. Parviainen, and N. Norton Polymyxin B protects horses against induced endotoxaemia in vivo Equine Vet J 36 2004 397 401
49. J.N. Moore, and M.H. Barton Treatment of endotoxemia Vet Clin North Am Equine Pract 19 2003 681 695
50. Official Journal of the European Union. Commission Regulation (EU) No 122/2013 of 12 February 2013 amending Regulation (EC) No 1950/2006 establishing, in accordance with Directive 2001/82/EC of the European Parliament and of the Council on the Community code relating to veterinary medicinal products, a list of substances essential for the treatment of Equidae. The European Commission. 2013 [accessed 09.06.15].
51. T. Timmerman, J. Dewulf, B. Catry, B. Feyen, G. Opsomer, A. de Kruif, and et al. Quantification and evaluation of antimicrobial drug use in group treatments for fattening pigs in Belgium Prev Vet Med 74 2006 251 263
52. B. Callens, D. Persoons, D. Maes, M. Laanen, M. Postma, F. Boyen, and et al. Prophylactic and metaphylactic antimicrobial use in Belgian fattening pig herds Prev Vet Med 106 2012 53 62
53. B. Pardon, B. Catry, J. Dewulf, D. Persoons, M. Hostens, K. De Bleecker, and et al. Prospective study on quantitative and qualitative antimicrobial and anti-inflammatory drug use in white veal calves J Antimicrob Chemother 67 2012 1027 1038
54. I. Kempf, M.A. Fleury, D. Drider, M. Bruneau, P. Sanders, C. Chauvin, and et al. What do we know about resistance to colistin in Enterobacteriaceae in avian and pig production in Europe? Int J Antimicrob Agents 42 2013 379 383
55. B. Catry, J. Dewulf, G. Opsomer, M. Vanrobaeys, A. Decostere, F. Haesebrouck, and et al. Antibioticumgebruik en antimicrobiële resistentie bij rundvee ontwikkeling van een surveillancesysteem op bedrijfsniveau [Use of antibiotics and antimicrobial resistance in cattle as evaluated by a herd-level surveillance system] 2007 University of Ghent, Faculty of Veterinary Medicine Ghent, Belgium
56. S. Menéndez González, A. Steiner, B. Gassner, and G. Regula Antimicrobial use in Swiss dairy farms: quantification and evaluation of data quality Prev Vet Med 95 2010 50 63
57. M. Moreno Survey of quantitative antimicrobial consumption in two different pig finishing systems Vet Rec 171 2012 325
58. D. Persoons, J. Dewulf, A. Smet, L. Herman, M. Heyndrickx, A. Martel, and et al. Antimicrobial use in Belgian broiler production Prev Vet Med 105 2012 320 325
59. MARAN 2009. Monitoring of antimicrobial resistance and antibiotic usage in animals in the Netherlands in 2009. 2009 [accessed 09.06.15].
60. Y. Xu, X. Tian, C. Ren, H. Huang, X. Zhang, X. Gong, and et al. Analysis of colistin A and B in fishery products by ultra performance liquid chromatography with positive electrospray ionization tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 899 2012 14 20
61. DANMAP 2011, Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark. Statens Serum Institut/National Veterinary Institute/National Food Institute. 2011 [accessed 09.06.15].
62. European Medicines Agency, Committee for Medicinal Products for Veterinary Use (EMA/CVMP). Opinion following an Article 35 referral for veterinary medicinal formulations containing colistin at 2 000 000 IU per ml and intended for administration in drinking water to food producing species. EMA/CVMP. 2010 [accessed 09.06.15].
63. M. Schindler, and M.J. Osborn Interaction of divalent cations and polymyxin B with lipopolysaccharide Biochemistry 18 1979 4425 4430
64. A.C. Gales, R.N. Jones, and H.S. Sader Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09) J Antimicrob Chemother 66 2011 2070 2074
65. M.D. David, and M.J. Gill Potential for underdosing and emergence of resistance in Acinetobacter baumannii during treatment with colistin J Antimicrob Chemother 61 2008 962 964
66. K. Drlica, and X. Zhao Mutant selection window hypothesis updated Clin Infect Dis 44 2007 681 688
67. P.S. McKinnon, J.A. Paladino, and J.J. Schentag Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections Int J Antimicrob Agents 31 2008 345 351
68. A.S. Michalopoulos, and M.E. Falagas Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients Ann Intensive Care 1 2011 1 6
69. D. Landman, C. Georgescu, D.A. Martin, and J. Quale Polymyxins revisited Clin Microbiol Rev 21 2008 449 465
70. M. Lamousin-White, and R.J. O'Callaghan Association between colistin resistance and broad-spectrum recipient deficiency in Klebsiella pneumoniae Antimicrob Agents Chemother 30 1986 964 965
71. R.J. O'Callaghan, K.M. Rousset, N.K. Harkess, M.L. Murray, A.C. Lewis, and W.L. Williams Analysis of increasing antibiotic resistance of Klebsiella pneumoniae relative to changes in chemotherapy J Infect Dis 138 1978 293 298
72. S.M. Moskowitz, M.K. Brannon, N. Dasgupta, M. Pier, N. Sgambati, A.K. Miller, and et al. PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients Antimicrob Agents Chemother 56 2012 1019 1030
73. K. Nummila, I. Kilpelainen, U. Zahringer, M. Vaara, and I.M. Helander Lipopolysaccharides of polymyxin B-resistant mutants of Escherichia coli are extensively substituted by 2-aminoethyl pyrophosphate and contain aminoarabinose in lipid A Mol Microbiol 16 1995 271 278
74. S.M. Moskowitz, R.K. Ernst, S.I. Miller, and PmrAB A two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A J Bacteriol 186 2004 575 579
75. M. Boll, J. Radziejewska-Lebrecht, C. Warth, D. Krajewska-Pietrasik, and H. Mayer 4-Amino-4-deoxy-l-arabinose in LPS of enterobacterial R-mutants and its possible role for their polymyxin reactivity FEMS Immunol Med Microbiol 8 1994 329 341
76. L. Fernandez, W.J. Gooderham, M. Bains, J.B. McPhee, I. Wiegand, and R.E. Hancock Adaptive resistance to the 'last hope' antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParR-ParS Antimicrob Agents Chemother 54 2010 3372 3382
77. B.A. Napier, E.M. Burd, S.W. Satola, S.M. Cagle, S.M. Ray, P. McGann, and et al. Clinical use of colistin induces cross-resistance to host antimicrobials in Acinetobacter baumannii MBio 4 2013 e00021-13
78. A. Beceiro, E. Llobet, J. Aranda, J.A. Bengoechea, M. Doumith, M. Hornsey, and et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system Antimicrob Agents Chemother 55 2011 3370 3379
79. A. Beceiro, S. Maharjan, T. Gaulton, M. Doumith, N.C. Soares, H. Dhanji, and et al. False extended-spectrum β-lactamase phenotype in clinical isolates of Escherichia coli associated with increased expression of OXA-1 or TEM-1 penicillinases and loss of porins J Antimicrob Chemother 66 2011 2006 2010
80. M. Reinés, E. Llobet, C.M. Llompart, D. Moranta, C. Pérez-Gutiérrez, and J.A. Bengoechea Molecular basis of Yersinia enterocolitica temperature-dependent resistance to antimicrobial peptides J Bacteriol 194 2012 3173 3188
81. L. Guo, K.B. Lim, J.S. Gunn, B. Bainbridge, R.P. Darveau, M. Hackett, and et al. Regulation of lipid A modifications by Salmonella typhimurium virulence genes phoP-phoQ Science 276 1997 250 253
82. Y. Lv, J. Xiao, Q. Liu, H. Wu, Y. Zhang, and Q. Wang Systematic mutation analysis of two-component signal transduction systems reveals EsrA-EsrB and PhoP-PhoQ as the major virulence regulators in Edwardsiella tarda Vet Microbiol 157 2012 190 199
83. J.A. Bengoechea, and M. Skurnik Temperature-regulated efflux pump/potassium antiporter system mediates resistance to cationic antimicrobial peptides in Yersinia Mol Microbiol 37 2000 67 80
84. E.S. Snitkin, A.M. Zelazny, J. Gupta, T.N. Palmore, P.R. Murray, and J.A. Segre Genomic insights into the fate of colistin resistance and Acinetobacter baumannii during patient treatment Genome Res 23 2013 1155 1162
85. L.O. Gentry Bacterial resistance Orthop Clin North Am 22 1991 379 388
86. A. Fite, S. Macfarlane, E. Furrie, B. Bahrami, J.H. Cummings, D.T. Steinke, and et al. Longitudinal analyses of gut mucosal microbiotas in ulcerative colitis in relation to patient age and disease severity and duration J Clin Microbiol 51 2013 849 856
87. S.L. Chua, S.Y. Tan, M.T. Rybtke, Y. Chen, S.A. Rice, S. Kjelleberg, and et al. Bis-(3′-5′)-cyclic dimeric GMP regulates antimicrobial peptide resistance in Pseudomonas aeruginosa Antimicrob Agents Chemother 57 2013 2066 2075
88. V. Balaji, S.S. Jeremiah, and P.R. Baliga Polymyxins: antimicrobial susceptibility concerns and therapeutic options Indian J Med Microbiol 29 2011 230 242
89. A.C. Gales, A.O. Reis, and R.N. Jones Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines J Clin Microbiol 39 2001 183 190
90. J.R. Lo-Ten-Foe, A.M. de Smet, B.M. Diederen, J.A. Kluytmans, and P.H. van Keulen Comparative evaluation of the VITEK 2, disk diffusion, Etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains Antimicrob Agents Chemother 51 2007 3726 3730
91. F. Boyen, F. Vangroenweghe, P. Butaye, E. De Graef, F. Castryck, P. Heylen, and et al. Disk prediffusion is a reliable method for testing colistin susceptibility in porcine E. coli strains Vet Microbiol 144 2010 359 362
92. J.A. Hindler, and R.M. Humphries Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli J Clin Microbiol 51 2013 1678 1684
93. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1, 2013. EUCAST, 2013. [accessed 09.06.15].
94. Y. Agerso, M. Torpdahl, C. Zachariasen, A. Seyfarth, A.M. Hammerum, and E.M. Nielsen Tentative colistin epidemiological cut-off value for Salmonella spp Foodborne Pathog Dis 9 2012 367 369
95. European Commission Commission implementing decision (2013/652/EU) on the monitoring and reporting of antimicrobial resistance in zoonotic and commensal bacteria. Official Journal of the European Union; 2013.
96. European Food Safety Authority, European Centre for Disease Prevention and Control (EFSA/ECDC). The European Union summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2010. EFSA/ECDC; 2012.
97. A. van Belkum, and W.M. Dunne Jr. Next-generation antimicrobial susceptibility testing J Clin Microbiol 51 2013 2018 2024
98. MARAN 2012. Monitoring of antimicrobial resistance and antibiotic usage in animals in the Netherlands, < http://www.wageningenur.nl/upload-mm/f/2/8/39a1adb8-497e-49d6-b696-9401f23089f5-MARAN2012.pdf.> 2012 [accessed 09.06.15].
99. E. Di Labio, G. Regula, A. Steiner, R. Miserez, A. Thomann, and U. Ledergerber Antimicrobial resistance in bacteria from Swiss veal calves at slaughter Zoonoses Public Health 54 2007 344 352
100. P. Geenen, H. Blaak, M. Koene, A. Havelaar, M. Leverstein-van Hall, M. Mulders, and et al. Antimicrobial resistance transmissible from food animals to humans - a risk profile Dutch Soc Vet Epidemiol Econ 2011 18
101. M. Aravena-Roman, T.J. Inglis, B. Henderson, T.V. Riley, and B.J. Chang Antimicrobial susceptibilities of Aeromonas strains isolated from clinical and environmental sources to 26 antimicrobial agents Antimicrob Agents Chemother 56 2012 1110 1112
102. F. Comandatore, D. Sassera, S. Ambretti, M.P. Landini, D. Daffonchio, P. Marone, and et al. Draft genome sequences of two multidrug resistant Klebsiella pneumoniae ST258 isolates resistant to colistin Genome Announc 1 2013 pii:e00113 pii:e212
103. A.J. Brink, J. Coetzee, C. Corcoran, C.G. Clay, D. Hari-Makkan, R.K. Jacobson, and et al. Emergence of OXA-48 and OXA-181 carbapenemases among Enterobacteriaceae in South Africa and evidence of in vivo selection of colistin resistance as a consequence of selective decontamination of the gastrointestinal tract J Clin Microbiol 51 2013 369 372
104. M.N. Balm, G. Ngan, R. Jureen, R.T. Lin, and J.W. Teo OXA-181-producing Klebsiella pneumoniae establishing in Singapore BMC Infect Dis 13 2013 58
105. E. Lesho, E.J. Yoon, P. McGann, E. Snesrud, Y. Kwak, M. Milillo, and et al. Emergence of colistin-resistance in extremely drug-resistant Acinetobacter baumannii containing a novel pmrCAB operon during colistin therapy of wound infections J Infect Dis 208 2013 1142 1151
106. V. Del Bono, D.R. Giacobbe, G. Orengo, C. Saffioti, A. Parisini, A. Marchese, and et al. Risk factors and mortality of bloodstream infections due to colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in a teaching hospital in Italy. Comparison with colistin-susceptible strains. Bloodstream infections caused by MDR Gram-negatives (poster session) Proceedings of the 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 27-30 April 2013; Berlin, Germany. ESCMID 2013
107. L. Galani, K. Ioannidis, G. Plakias, I. Karaiskos, F. Baziaka, C. Paskalis, and et al. In the era of polymyxins use: emergence of colistin resistance in Klebsiella pneumoniae Proceedings of the First International Conference on Polymyxins 2-4 May 2013; Prato, Italy May 2013 1865 . [accessed 09.06.15].
108. K. Dafopoulou, A. Poulou, Y. Nait Chabane, J. Hardouin, P. Cosette, M. Labrou, and et al. Colistin-resistance development in Acinetobacter baumannii during colistin treatment associated with lipopolysaccharide (LPS) modification, impaired biofilm production and colistin-mediated cell death Proceedings of the 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 27-30 April 2013; Berlin, Germany. ESCMID 2013
109. D. Marchaim, T. Chopra, J.M. Pogue, F. Perez, A.M. Hujer, S. Rudin, and et al. Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan Antimicrob Agents Chemother 55 2011 593 599
110. C. Mammina, C. Bonura, F. Di Bernardo, A. Aleo, T. Fasciana, C. Sodano, and et al. Ongoing spread of colistin-resistant Klebsiella pneumoniae in different wards of an acute general hospital, Italy, June to December 2011 Eurosurveillance 17 2012 pii:20248
111. B. Callens, F. Boyen, B. Catry, A. Ingenbleek, P. Butaye, F. Haesebrouck, and et al. Reply to Letter to the Editor by Moore and Elborn (2012) concerning the manuscript 'Prophylactic and metaphylactic antimicrobial use in Belgian fattening pig herds' by B Callens et al. (2012) Prev Vet Med 107 2012 288 290
112. A.J. Houben, E.A. Oostdijk, P.H. van der Voort, J.C. Monen, M.J. Bonten, A.K. van der Bij, and et al. Selective decontamination of the oropharynx and the digestive tract, and antimicrobial resistance: a 4 year ecological study in 38 intensive care units in The Netherlands J Antimicrob Chemother 69 2014 797 804